Scandion Oncology A/S (SCOL) — Strategic Asset Allocation Index
Scandion Oncology A/S (SCOL) has a Strategic Asset Allocation Index of 3.4% as of June 2023. Strategic assets (PP&E of Skr1.77 Million plus long-term investments of Skr-) total Skr1.77 Million, measured against net assets of Skr52.27 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Scandion Oncology A/S Strategic Asset Allocation Index (2019–2022)
This chart shows how Scandion Oncology A/S's Strategic Asset Allocation Index has evolved across 4 annual periods from 2019 to 2022. As of June 2023, the index stands at 3.4%, representing strategic assets of Skr1.77 Million against net assets of Skr52.27 Million SEK. Explore Scandion Oncology A/S cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Scandion Oncology A/S (2019–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Scandion Oncology A/S from 2019 to 2022, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see SCOL company net worth.
| Year | SAAI | Strategic Assets (SEK) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 3.2% | Skr2.26 Million | Skr2.26 Million | Skr- | Skr70.33 Million | ▲ +1.7 pp |
| 2021 | 1.5% | Skr1.60 Million | Skr1.60 Million | Skr- | Skr104.54 Million | ▲ +1.2 pp |
| 2020 | 0.3% | Skr448.00K | Skr448.00K | Skr- | Skr155.87 Million | ▼ -0.6 pp |
| 2019 | 0.9% | Skr171.00K | Skr171.00K | Skr- | Skr18.34 Million | — |